Short Interest in Astellas Pharma Inc. (OTCMKTS:ALPMY) Drops By 98.5%

Astellas Pharma Inc. (OTCMKTS:ALPMY) saw a large drop in short interest during the month of April. As of April 15th, there was short interest totalling 900 shares, a drop of 98.5% from the March 31st total of 60,400 shares. Based on an average daily trading volume, of 885,400 shares, the days-to-cover ratio is presently 0.0 days. Approximately 0.0% of the shares of the company are short sold.

Astellas Pharma Stock Up 5.2 %

ALPMY stock opened at $10.07 on Monday. The company has a market capitalization of $18.22 billion, a P/E ratio of -45.77 and a beta of 0.31. Astellas Pharma has a 12 month low of $8.37 and a 12 month high of $13.14. The firm’s fifty day simple moving average is $9.60 and its 200-day simple moving average is $10.04. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.04 and a quick ratio of 0.80.

Astellas Pharma (OTCMKTS:ALPMY) last posted its quarterly earnings results on Friday, April 25th. The company reported $0.27 EPS for the quarter, beating the consensus estimate of $0.15 by $0.12. The company had revenue of $3.22 billion for the quarter, compared to analyst estimates of $3.02 billion. Astellas Pharma had a negative net margin of 3.10% and a positive return on equity of 13.69%. As a group, equities research analysts forecast that Astellas Pharma will post 0.42 earnings per share for the current year.

About Astellas Pharma

Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.